UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter)
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On October 12, 2022, INVO Bioscience, Inc. (the “Company”) held its annual meeting of stockholders (the “Meeting”). The total number of shares entitled to vote at the Meeting were 12,169,714 and there were present at the Meeting, in person or by proxy, 9,074,727 shares, which constituted a quorum for the Meeting. At the Meeting, the stockholders voted:
(1) to elect Steven Shum, Trent Davis, Barbara Ryan, Jeffrey Segal, Matthew Szot and Rebecca Messina to the board of directors of the Company until the next annual meeting of stockholders;
(2) to ratify the selection of M&K CPAS, PLLC as the Company’s independent registered public accounting firm, for the fiscal year ending December 31, 2022; and
(3) to approve the Company’s Second Amended and Restated 2019 Stock Incentive Plan.
The final results of the stockholders’ votes at the Meeting are set forth below:
Proposal 1: Election of Directors
| Nominee | For | Withheld | Broker Non-Votes | |||||||||
| Steven Shum | 3,842,573 | 84,660 | 5,147,494 | |||||||||
| Trent Davis | 3,297,799 | 629,434 | 5,147,494 | |||||||||
| Barbara Ryan | 3,304,152 | 623,081 | 5,147,494 | |||||||||
| Jeffrey Segal | 3,304,054 | 623,179 | 5,147,494 | |||||||||
| Matthew Szot | 3,303,500 | 623,733 | 5,147,494 | |||||||||
| Rebecca Messina | 3,875,453 | 51,780 | 5,147,494 | |||||||||
Proposal 2: Ratification of Appointment of M&K CPAS, PLLC as Independent Registered Public Accounting Firm
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES | |||||||||||
| 8,888,232 | 182,404 | 4,091 | 0 | |||||||||||
Proposal 3: Approval of Second Amended and Restated 2019 Stock Incentive Plan
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES | |||||||||||
| 3,247,429 | 663,733 | 16,071 | 5,147,494 | |||||||||||
| Exhibit | Description | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| -2- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| INVO BIOSCIENCE, INC. | ||
| By: | /s/ Steven Shum | |
| Name: | Steven Shum | |
| Title: | Chief Executive Officer | |
| Dated: October 14, 2022 | ||
| -3- |